Novartis' BAF312 meets main goal in secondary progressive multiple sclerosis trial - Pharmaceutical Business Review

Pharmaceutical Business Review

Novartis' BAF312 meets main goal in secondary progressive multiple sclerosis trial Pharmaceutical Business Review A phase III study, assessing the efficacy and safety of Novartis' BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS), met its primary endpoint of a reduction in the risk of disability progression, versus placebo. Novartis claims that ... Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MSNasdaq all 3 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNG8tGsGFwcrGU2PlfsEFO5vwZoPjw&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779188673549&ei=rqi-V-jQO5Xj3AGSgJ7gBg&url=http://clinicaltrials.pharmaceutical-business-review.com/news/novartis-baf312-meets-main-goal-in-secondary-progressive-multiple-sclerosis-trial-250816-4988439
via IFTTT